Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. aob
Show results for
Products
Services

Companies

News
Articles

Refine by
Date

  • Older

Aob Articles & Analysis

8 news found

AOBiome Therapeutics Announces Appointment of Dr. Judith Ng Cashin as Chief Medical Officer

AOBiome Therapeutics Announces Appointment of Dr. Judith Ng Cashin as Chief Medical Officer

About Ammonia Oxidizing Bacteria (AOB) AOBiome's AOB platform is a patented, proprietary, topical and intranasal formulation incorporating a single strain of beneficial AOB, Nitrosomonas eutropha. The platform is designed to repopulate the skin or nasal microbiome with AOB. Once deployed, AOB produces nitric ...

ByAOBiome Therapeutic, LLC


AOBiome`s 30 Patient Study Using New Shelf-Stable Formulation of its Ammonia Oxidizing Bacteria (AOB) Shows Significant Reduction of Itch Levels in Both Pediatric and Adult Subjects who Suffer from Eczema

AOBiome`s 30 Patient Study Using New Shelf-Stable Formulation of its Ammonia Oxidizing Bacteria (AOB) Shows Significant Reduction of Itch Levels in Both Pediatric and Adult Subjects who Suffer from Eczema

Newly completed study aimed to understand the safety and potential benefits of the AOB’s cellular structure without the production of nitric oxide and nitrite. ...

ByAOBiome Therapeutic, LLC


AOBiome Reports Successful Clinical Trials (Phase 2a in Adults and Phase 1b in Pediatrics) in Pruritus (Itch) Associated with Atopic Dermatitis: Initiates Phase 2b Clinical Trial in Adults

AOBiome Reports Successful Clinical Trials (Phase 2a in Adults and Phase 1b in Pediatrics) in Pruritus (Itch) Associated with Atopic Dermatitis: Initiates Phase 2b Clinical Trial in Adults

About Ammonia Oxidizing Bacteria (AOB) AOBiome's AOB platform is a patented, proprietary, topical and intranasal formulation incorporating a single strain of beneficial AOB, Nitrosomonas eutropha. The platform is designed to repopulate the skin or nasal microbiome with AOB. Once deployed, AOB produces nitric ...

ByAOBiome Therapeutic, LLC


AOBiome Reports Successful Clinical Trials (Phase 2a in Adults and Phase 1b in Pediatrics) in Pruritus (Itch) Associated with Atopic Dermatitis: Initiates Phase 2b Clinical Trial in Adults

AOBiome Reports Successful Clinical Trials (Phase 2a in Adults and Phase 1b in Pediatrics) in Pruritus (Itch) Associated with Atopic Dermatitis: Initiates Phase 2b Clinical Trial in Adults

About Ammonia Oxidizing Bacteria (AOB) AOBiome's AOB platform is a patented, proprietary, topical and intranasal formulation incorporating a single strain of beneficial AOB, Nitrosomonas eutropha. The platform is designed to repopulate the skin or nasal microbiome with AOB. Once deployed, AOB produces nitric ...

ByAOBiome Therapeutic, LLC


AOBiome Doses First Patient in Phase 1b Clinical Trial of B244 for the Treatment of Pediatric Atopic Dermatitis

AOBiome Doses First Patient in Phase 1b Clinical Trial of B244 for the Treatment of Pediatric Atopic Dermatitis

The clinical trial is an open-label, multicenter, Phase 1b study of B244, a first-in-class, topical formulation of beneficial ammonia oxidizing bacteria (“AOB”), delivered as a topical spray twice daily and is designed to assess safety and tolerability in 36 pediatric patients aged 2 to 17 years with mild to moderate atopic dermatitis over a 28-day period. ...

ByAOBiome Therapeutic, LLC


AOBiome Therapeutics Expands Intellectual Property Estate with Issuance of U.S. Patent for Use of Ammonia Oxidizing Bacteria (AOB) for the Treatment of Eczema

AOBiome Therapeutics Expands Intellectual Property Estate with Issuance of U.S. Patent for Use of Ammonia Oxidizing Bacteria (AOB) for the Treatment of Eczema

(“AOBiome”), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent covering the use of the Company’s Ammonia Oxidizing Bacteria ...

ByAOBiome Therapeutic, LLC


AOBiome Therapeutics Announces the Expansion of its Board of Directors

AOBiome Therapeutics Announces the Expansion of its Board of Directors

About Ammonia Oxidizing Bacteria (AOB) AOBiome's AOB platform includes patented, proprietary, topical and intranasal formulations which incorporate a single strain of AOB, Nitrosomonas eutropha. The platform is designed to repopulate the skin or nasal microbiome with AOB. Once deployed, AOB consume ammonia and ...

ByAOBiome Therapeutic, LLC


AOBiome Therapeutics Announces Election of Dr. Jun Wang as Chairman of the Board of Directors

AOBiome Therapeutics Announces Election of Dr. Jun Wang as Chairman of the Board of Directors

AOBiome has propelled its programs forward, leading and innovating unique approaches with its AOB, including industry-first intranasal administration in multiple applications. ...

ByAOBiome Therapeutic, LLC

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT